

SAFETY DATA SHEETS

This SDS packet was issued with item:

078056551

N/A

Dolorex

Page 1 of 4

Section 1: Identification of the Substance and Supplier

Product name	Dolorex Liquid containing 1-1.5% butorphanol tartrate
Recommended use	Centrally acting narcotic agonist-antagonist analgesic.
Company details	Intervet Limited 12 Shakespeare Ave, Upper Hutt Phone: 0800 447 838, Fax 0800 424 838 Website: www.intervet.co.nz Hours 8am – 5 pm, Mon – Fri
Emergency telephone	0800 764 766 (0800 POISON) 24 hours human health 0800 243 622 (0800 CHEMCALL) 24 hours
Date of preparation	October 2008

Section 2: Hazards Identification

Hazard classifications	6.9B
Priority identifiers	Warning
Secondary identifier	6.9B May cause target organ damage through prolonged or repeated oral exposure at high doses.
Risk & Safety Phrases	R48/22 Harmful: danger of serious damage to health by prolonged exposure if swallowed

Section 3: Composition/Information on Ingredients

Chemical name	CAS number	Concentration
Butorphanol tartrate	58786-99-5	0.019g/mL

Section 4: First Aid Measures

Necessary first aid measures	<p>ACCIDENTIAL INJECTION: Wash and disinfect self injection injuries. Seek medical advice if irritancy or an allergic response occurs – show this SDS.</p> <p>SKIN CONTACT: In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.</p> <p>EYE CONTACT: In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.</p> <p>INGESTION: Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or National Poisons Centre. If symptoms persist, consult a doctor.</p>
Required instructions	For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a

Dolorex

Page 2 of 4

doctor.

Notes for medical personnel

Butorphanol is a potent analgesic with appreciable narcotic antagonist activity. Butorphanol is absorbed orally or parentally. The human therapeutic dose is 1-4mg IM or 0.2-2mg IV. Peak plasma concentration occurs ½ - 1 hour after IM injection and 1-1½ hours after oral administration. Pharmacological effect lasts 3-4 hrs. For gross over dosage, Naloxone is the specific antagonist.

Section 5: Fire Fighting Measures

Type of hazard	Not classified as flammable
Fire hazard properties	Not applicable
Regulatory requirements	Not applicable
Extinguishing media and methods	Carbon dioxide (CO ₂), extinguishing powder or water spray
Hazchem code	None allocated
Recommended protective clothing	Wear self-contained breathing apparatus (SCBA) plus protective gloves.

Section 6: Accidental Release Measures

Emergency procedures	Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Adsorb spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal.
-----------------------------	---

Section 7: Handling and Storage

Precautions for safe handling	Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.
Regulatory requirements	Not required
Handling practices	Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.
Approved handlers	Not required.
Conditions for safe storage	See below.
Store site requirements	Store in original container and below 25°C. Keep out of reach of children
Packaging	Schedule 4

Dolorex

Section 8: Exposure Control/Personal Protection

Workplace exposure standards	No WES is set for this substance at this time.
Application in the workplace	Ensure adequate ventilation. Keep container sealed when not in use.
Exposure standards outside the workplace	No TEL are required for this substance at this time No EEL is set for this substance at this time
Personal protection	Wear chemical resistant gloves, facemask or goggles.

Section 9: Physical and Chemical Properties

Appearance	Clear, colourless liquid with characteristic odour.
Boiling Point	Approximately 100°C
Melting Point	Approximately 0°C
Vapour Pressure	2.37 kPa at 20°C
Specific Gravity	1.114
Solubility (H ₂ O)	Completely soluble in water.
Percent Volatiles	Not determined
Evaporation Rate	Not determined

Section 10: Stability and Reactivity

Stability of the substance	Stable under normal conditions.
Conditions to avoid	Avoid high temperatures
Material to avoid	Avoid food products
Hazardous decomposition products	No dangerous decomposition is expected if used according to manufacturer's specifications.

Section 11: Toxicological Information

Acute effects for individual ingredients only

ORAL	Butorphanol: Orally 10mg/kg gives slight cardiovascular and respiratory depression. NOAEL 0.3mg.kg bw/day Rat oral LD50 = 315mg/kg
TEL	No TELs are required for this substance at this time.

Chronic/long term effects for individual ingredients only

Section 12: Environmental Information

Effects for individual ingredients only.

Dolorex

Page 4 of 4

EEL No EEL is set for this substance at this time.

Section 13: Disposal Considerations

Disposal information	Disposal Dispose of this product only by using according to the label, or at an approved landfill, or other approved facility. Container Disposal Bury in an approved landfill or other approved facility.
Reference	Current version of NZS 8409 Management of Agrichemicals

Section 14: Transport Information

Relevant information	Not classified as a dangerous good for transport
-----------------------------	--

Section 15: Regulatory Information

Regulatory status	HSNO Approval Code: HSR001963. For a full listing of controls see www.ermanz.govt.nz ACVM registration number: A06877 For conditions of registration see www.nzfsa.govt.nz/acvm Prescription Animal Remedy (P.A.R) Class II For use only by, in the presence of, or under the control of a veterinarian.
HSNO and ACVM controls	-

Section 16: Other Information

Additional information	Dolorex is a trademark of Intervet Limited
-------------------------------	--

Intervet Limited urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Intervet Limited extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

SAFETY DATA SHEET

Dolorex™

Section 1: Identification of the Substance and Supplier

Product name	Dolorex Liquid containing 1-1.5% butorphanol tartrate
Recommended use	Centrally acting narcotic agonist-antagonist analgesic.
Company details	MSD Animal Health, 33 Whakatiki Street, Upper Hutt Phone: 0800 800 543 Fax: 0800 808 100 Website: www.msd-animal-health.co.nz Hours: 8 am – 5 pm, Mon – Fri
Emergency telephone	0800 764 766 (0800 POISON) 24 hours human health 0800 243 622 (0800 CHEMCALL) 24 hours
Date of preparation	August 2011

Section 2: Hazards Identification

Hazard classifications	6.9B
Priority identifiers	WARNING
Secondary identifier	6.9B May cause target organ damage through prolonged or repeated oral exposure at high doses.
Risk & Safety Phrases	R48/22 Harmful: danger of serious damage to health by prolonged exposure if swallowed

Section 3: Composition/Information on Ingredients

Chemical name	CAS number	Concentration
Butorphanol tartrate	58786-99-5	0.019g/mL

Section 4: First Aid Measures

Necessary first aid measures	<p>ACCIDENTIAL INJECTION Wash and disinfect self injection injuries. Seek medical advice if irritancy or an allergic response occurs – show this SDS.</p> <p>SKIN CONTACT In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.</p> <p>EYE CONTACT In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.</p> <p>INGESTION Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or National Poisons Centre. If symptoms persist, consult a doctor.</p>
Required instructions	For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.
Notes for medical	Butorphanol is a potent analgesic with appreciable narcotic antagonist activity.

SAFETY DATA SHEET

Dolorex™

Page 2 of 4

personnel

Butorphanol is absorbed orally or parentally. The human therapeutic dose is 1-4mg IM or 0.2-2mg IV. Peak plasma concentration occurs ½ - 1 hour after IM injection and 1-1½ hours after oral administration. Pharmacological effect lasts 3-4 hrs. For gross over dosage, Naloxone is the specific antagonist.

Section 5: Fire Fighting Measures

Type of hazard	Not classified as flammable
Fire hazard properties	Not applicable
Regulatory requirements	Not applicable
Extinguishing media and methods	Carbon dioxide (CO ₂), extinguishing powder or water spray
Hazchem code	None allocated
Recommended protective clothing	Wear self-contained breathing apparatus (SCBA) plus protective gloves.

Section 6: Accidental Release Measures

Emergency procedures	Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Adsorb spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal.
-----------------------------	---

Section 7: Handling and Storage

Precautions for safe handling	Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.
Regulatory requirements	Not required
Handling practices	Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.
Approved handlers	Not required.
Conditions for safe storage	Store in original container in a cool, dry, ventilated place away from direct heat or direct sunlight. Keep container sealed when not in use. Keep out of reach of children.
Store site requirements	Store in original container and below 25°C.
Packaging	Schedule 4

SAFETY DATA SHEET

Dolorex™

Section 8: Exposure Control/Personal Protection

Workplace exposure standards	No WES is set for this substance at this time.
Application in the workplace	Ensure adequate ventilation. Keep container sealed when not in use.
Exposure standards outside the workplace	No TEL are required for this substance at this time No EEL is set for this substance at this time
Personal protection	Wear chemical resistant gloves, facemask or goggles.

Section 9: Physical and Chemical Properties

Appearance	Clear solution
Boiling Point	Approximately 100°C
Melting Point	Approximately 0°C
Vapour Pressure	2.37 kPa at 20°C
Specific Gravity	1.114
Solubility (H ₂ O)	Completely soluble in water
Percent Volatiles	Not determined
Evaporation Rate	Not determined

Section 10: Stability and Reactivity

Stability of the substance	Stable under normal conditions.
Conditions to avoid	Avoid high temperatures
Material to avoid	Avoid food products
Hazardous decomposition products	No dangerous decomposition is expected.

Section 11: Toxicological Information

Acute effects for individual ingredients only

ORAL	Butorphanol: Orally 10mg/kg gives slight cardiovascular and respiratory depression. NOAEL 0.3mg.kg bw/day Rat oral LD50 = 315mg/kg
TEL	No TELs are required for this substance at this time.

Chronic/long term effects for individual ingredients only

Section 12: Environmental Information

Effects for individual ingredients only.

SAFETY DATA SHEET

Dolorex™

EEL No EEL is set for this substance at this time.

Section 13: Disposal Considerations

Disposal information	Disposal Dispose of unused contents in a suitable landfill.
	Container Disposal Dispose of empty container by burying in a suitable landfill.
Reference	Current version of NZS 8409 Management of Agrichemicals

Section 14: Transport Information

Relevant information Not classified as a dangerous good for transport

Section 15: Regulatory Information

Regulatory status HSNO Approval Code: HSR001963.
For a full listing of controls see www.epa.govt.nz

ACVM registration number: A06877
For conditions of registration see www.foodsafety.govt.nz

RESTRICTED VETERINARY MEDICINE

Section 16: Other Information

Additional information Dolorex is a trademark.

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Intervet Limited extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).